Devyser Diagnostics AB (publ) (DVYSR.ST)
Stockholm · SEK · Healthcare · Medical Devices
SEK 55.00 (+9.13%) as of
Key statistics
- Market cap
- 928.94M
- P/E (TTM)
- 59.78
- Forward P/E
- 90.16
- EPS (TTM)
- 0.92
- Dividend yield
- 0.00%
- 52-week range
- 48.50 – 138.60
- Beta
- 0.82
- Revenue (TTM)
- 250.3M
- Profit margin
- 6.15%
- Analyst target
- SEK 97.13
- Volume
- 52.27k
About Devyser Diagnostics AB (publ)
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Årsta, Sweden
- Employees
- 110
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.